MBX Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
No thesis.
MBX Biosciences, Inc.
55.27
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Frazier Life Sciences ManagementFrazier Life Sciences | $367.2M | 11.86% | 0.00% | |
| 2 | FMRFMR | $293.8M | 9.49% | +81.25% | |
| 3 | Wellington Management GroupWellington | $274.8M | 8.88% | +55.95% | |
| 4 | NEA ManagementNEA | $199.5M | 6.45% | 0.00% | |
| 5 | Orbimed AdvisorsOrbimed | $189.3M | 6.12% | −5.75% | |
| 6 | BlackRockBlackRockindex-like | $183.5M | 5.93% | +13.00% | |
| 7 | Paradigm Biocapital AdvisorsParadigm Biocapital | $138.4M | 4.47% | new | |
| 8 | NVP AssociatesNVP | $117.9M | 3.81% | 0.00% | |
| 9 | Deep Track CapitalDeep Track Capital | $95.6M | 3.09% | −37.17% | |
| 10 | Polar Capital HoldingsPolar Capital | $88.8M | 2.87% | −0.84% | |
| 11 | Vanguard Capital ManagementVanguardindex-like | $81.6M | 2.64% | −0.01% | |
| 12 | Aaron Wealth AdvisorsAaron Wealth | $64.5M | 2.08% | −0.03% | |
| 13 | Driehaus Capital ManagementDriehaus | $58.3M | 1.88% | +3.77% | |
| 14 | Kynam Capital ManagementKynam | $51.6M | 1.67% | 0.00% | |
| 15 | Woodline PartnersWoodline Partners | $49.7M | 1.61% | 0.00% | |
| 16 | Eventide Asset ManagementEventide | $48.2M | 1.56% | −1.85% | |
| 17 | State StreetState Streetindex-like | $47.7M | 1.54% | +9.81% | |
| 18 | T. Rowe Price AssociatesT. Rowe Price | $45.0M | 1.45% | −20.82% | |
| 19 | Parkman Healthcare PartnersParkman Healthcare Partners | $44.2M | 1.43% | +0.02% | |
| 20 | Geode Capital ManagementGeodeindex-like | $42.7M | 1.38% | +15.32% | |
| 21 | BraidwellBraidwell | $39.2M | 1.27% | −52.37% | |
| 22 | TCG Crossover ManagementTCG Crossover | $35.9M | 1.16% | 0.00% | |
| 23 | Cormorant Asset ManagementCormorant | $30.4M | 0.98% | −50.89% | |
| 24 | Soleus Capital ManagementSoleus | $28.4M | 0.92% | +188.03% | |
| 25 | Goldman Sachs GroupGoldman Sachs | $25.3M | 0.82% | +0.23% |
175 managers report $3.1B of MBX Biosciences on form 13F for the quarter ended Jun 30 '26. 20 of them hold 80% of it; Frazier Life Sciences is largest at 11.86%.
Largest filed tie
—
Expected move
Inputsspot 55.87exp Nov 20ATM strike 55ATM straddle 12.50IV 118%